|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:FCHSD2-NBPF4 (FusionGDB2 ID:29923) |
Fusion Gene Summary for FCHSD2-NBPF4 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: FCHSD2-NBPF4 | Fusion gene ID: 29923 | Hgene | Tgene | Gene symbol | FCHSD2 | NBPF4 | Gene ID | 9873 | 148545 |
| Gene name | FCH and double SH3 domains 2 | NBPF member 4 | |
| Synonyms | NWK|NWK1|SH3MD3 | - | |
| Cytomap | 11q13.4 | 1p13.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | F-BAR and double SH3 domains protein 2FCH and double SH3 domains protein 2SH3 multiple domains 3SH3 multiple domains protein 3caromnervous wreck homologprotein nervous wreck 1 | neuroblastoma breakpoint family member 4 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | O94868 | Q96M43 | |
| Ensembl transtripts involved in fusion gene | ENST00000311172, ENST00000409314, ENST00000409418, ENST00000458644, ENST00000409853, ENST00000409263, | ENST00000415641, | |
| Fusion gene scores | * DoF score | 43 X 26 X 16=17888 | 1 X 1 X 1=1 |
| # samples | 59 | 1 | |
| ** MAII score | log2(59/17888*10)=-4.92213332859399 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(1/1*10)=3.32192809488736 | |
| Context | PubMed: FCHSD2 [Title/Abstract] AND NBPF4 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | FCHSD2(72851076)-NBPF4(108777033), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Fusion gene breakpoints across FCHSD2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across NBPF4 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | BRCA | TCGA-B6-A0I9-01A | FCHSD2 | chr11 | 72851076 | - | NBPF4 | chr1 | 108777033 | - |
| ChimerDB4 | BRCA | TCGA-B6-A0I9-01A | FCHSD2 | chr11 | 72851076 | - | NBPF4 | chr1 | 108777033 | - |
Top |
Fusion Gene ORF analysis for FCHSD2-NBPF4 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000311172 | ENST00000415641 | FCHSD2 | chr11 | 72851076 | - | NBPF4 | chr1 | 108777033 | - |
| In-frame | ENST00000409314 | ENST00000415641 | FCHSD2 | chr11 | 72851076 | - | NBPF4 | chr1 | 108777033 | - |
| In-frame | ENST00000409418 | ENST00000415641 | FCHSD2 | chr11 | 72851076 | - | NBPF4 | chr1 | 108777033 | - |
| 5UTR-3CDS | ENST00000458644 | ENST00000415641 | FCHSD2 | chr11 | 72851076 | - | NBPF4 | chr1 | 108777033 | - |
| 5UTR-3CDS | ENST00000409853 | ENST00000415641 | FCHSD2 | chr11 | 72851076 | - | NBPF4 | chr1 | 108777033 | - |
| intron-3CDS | ENST00000409263 | ENST00000415641 | FCHSD2 | chr11 | 72851076 | - | NBPF4 | chr1 | 108777033 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000409314 | FCHSD2 | chr11 | 72851076 | - | ENST00000415641 | NBPF4 | chr1 | 108777033 | - | 1541 | 288 | 169 | 1176 | 335 |
| ENST00000409418 | FCHSD2 | chr11 | 72851076 | - | ENST00000415641 | NBPF4 | chr1 | 108777033 | - | 1756 | 503 | 384 | 1391 | 335 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000409314 | ENST00000415641 | FCHSD2 | chr11 | 72851076 | - | NBPF4 | chr1 | 108777033 | - | 0.010153873 | 0.9898461 |
| ENST00000409418 | ENST00000415641 | FCHSD2 | chr11 | 72851076 | - | NBPF4 | chr1 | 108777033 | - | 0.011722693 | 0.98827726 |
Top |
Fusion Genomic Features for FCHSD2-NBPF4 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for FCHSD2-NBPF4 |
| Go to FGviewer for the breakpoints of chr11:72851076-chr1:108777033 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| FCHSD2 | NBPF4 |
| FUNCTION: Adapter protein that plays a role in endocytosis via clathrin-coated pits. Contributes to the internalization of cell surface receptors, such as integrin ITGB1 and transferrin receptor (PubMed:29887380). Promotes endocytosis of EGFR in cancer cells, and thereby contributes to the down-regulation of EGFR signaling (PubMed:30249660). Recruited to clathrin-coated pits during a mid-to-late stage of assembly, where it is required for normal progress from U-shaped intermediate stage pits to terminal, omega-shaped pits (PubMed:29887380). Binds to membranes enriched in phosphatidylinositol 3,4-bisphosphate or phosphatidylinositol 3,4,5-trisphosphate (PubMed:29887380). When bound to membranes, promotes actin polymerization via its interaction with WAS and/or WASL which leads to the activation of the Arp2/3 complex. Does not promote actin polymerisation in the absence of membranes (PubMed:29887380). {ECO:0000269|PubMed:29887380, ECO:0000269|PubMed:30249660}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | NBPF4 | chr11:72851076 | chr1:108777033 | ENST00000415641 | 8 | 15 | 400_503 | 342.6666666666667 | 639.0 | Domain | Olduvai 3 |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000311172 | - | 1 | 19 | 356_397 | 0 | 685.0 | Coiled coil | Ontology_term=ECO:0000255 |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000409418 | - | 2 | 20 | 356_397 | 39.666666666666664 | 741.0 | Coiled coil | Ontology_term=ECO:0000255 |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000409853 | - | 1 | 16 | 356_397 | 0 | 516.0 | Coiled coil | Ontology_term=ECO:0000255 |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000311172 | - | 1 | 19 | 718_721 | 0 | 685.0 | Compositional bias | Note=Poly-Pro |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000409418 | - | 2 | 20 | 718_721 | 39.666666666666664 | 741.0 | Compositional bias | Note=Poly-Pro |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000409853 | - | 1 | 16 | 718_721 | 0 | 516.0 | Compositional bias | Note=Poly-Pro |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000311172 | - | 1 | 19 | 469_530 | 0 | 685.0 | Domain | SH3 1 |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000311172 | - | 1 | 19 | 8_282 | 0 | 685.0 | Domain | F-BAR |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000409418 | - | 2 | 20 | 469_530 | 39.666666666666664 | 741.0 | Domain | SH3 1 |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000409418 | - | 2 | 20 | 8_282 | 39.666666666666664 | 741.0 | Domain | F-BAR |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000409853 | - | 1 | 16 | 469_530 | 0 | 516.0 | Domain | SH3 1 |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000409853 | - | 1 | 16 | 8_282 | 0 | 516.0 | Domain | F-BAR |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000311172 | - | 1 | 19 | 567_629 | 0 | 685.0 | Region | Required and sufficient for location at clathrin-coated pits |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000409418 | - | 2 | 20 | 567_629 | 39.666666666666664 | 741.0 | Region | Required and sufficient for location at clathrin-coated pits |
| Hgene | FCHSD2 | chr11:72851076 | chr1:108777033 | ENST00000409853 | - | 1 | 16 | 567_629 | 0 | 516.0 | Region | Required and sufficient for location at clathrin-coated pits |
| Tgene | NBPF4 | chr11:72851076 | chr1:108777033 | ENST00000415641 | 8 | 15 | 10_43 | 342.6666666666667 | 639.0 | Coiled coil | Ontology_term=ECO:0000255 | |
| Tgene | NBPF4 | chr11:72851076 | chr1:108777033 | ENST00000415641 | 8 | 15 | 69_115 | 342.6666666666667 | 639.0 | Coiled coil | Ontology_term=ECO:0000255 | |
| Tgene | NBPF4 | chr11:72851076 | chr1:108777033 | ENST00000415641 | 8 | 15 | 174_261 | 342.6666666666667 | 639.0 | Domain | Olduvai 1 | |
| Tgene | NBPF4 | chr11:72851076 | chr1:108777033 | ENST00000415641 | 8 | 15 | 326_399 | 342.6666666666667 | 639.0 | Domain | Olduvai 2 |
Top |
Fusion Gene Sequence for FCHSD2-NBPF4 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000409314_ENST00000415641_TCGA-B6-A0I9-01A_FCHSD2_chr11_72851076_-_NBPF4_chr1_108777033_length(transcript)=1541nt_BP=288nt GTCCGCCTGCCGCCCGCTGGCCTGCTCCCTCCGGGGCAAGTCTTGCTTCTTAAGCGCTCCTTTCACACACGCGCGCGCTCGCTGGGCCGT CCCCTCCTCTCCGGCCCTCCTCCTCCTCCTGGTCCTTGCTAACGCTGCCGTCGGGGAGGATTGATGTCCCTTCAGCATCATGCAGCCGCC GCCGAGGAAGGTGAAAGTTACACAAGAACTGAAAAACATTCAAGTTGAGCAGATGACAAAACTTCAAGCCAAACATCAAGCAGAATGTGA TTTGCTTGAAGATATGAGGCTCAGCAGGGGACCGCTGAGAGTGGACAAGCATGAAATCCCCCAGGAGTCACTGGATGGATGTTGCTTGAC TCCTTCCATCCTTCCTGACCTGACTCCCTCCTACCACCCTTATTGGAGCACTTTGTACTCTTTTGAAGACAAGCAAGTCAGCTTGGCTCT TGTAGACAAAATTAAAAAGGATCAAGAGGAGATAGAAGACCAAAGCCCACCATGCCCCAGGCTCAGCCAGGAGCTGCCAGAGGTGAAGGA GCAGGAAGTCCCAGAGGACTCTGTGAATGAAGTTTACTTGACTCCCTCAGTTCACCATGACGTGTCTGACTGCCACCAGCCTTATAGCAG CACCTTGTCCTCATTGGAGGATCAGCTTGCCTGCTCTGCTCTGGATGTAGCCTCCCCCACCGAGGCGGCCTGTCCCCAAGGGACTTGGAG TGGAGACTTGAGCCACCACCAGTCAGAGGTGCAAGTTTCACAGGCACAGCTGGAACCAAGCACCCTGGTGCCCAGTTGTCTGCGACTACA GCTGGATCAAGGGTTCCACTGTGGGAACGGCTTGGCCCAGCGGGGCCTTTCCTCCACCACCTGCAGCTTCTCAGCCAATGCTGATTCTGG GAACCAATGGCCCTTCCAAGAGCTGGTTTTAGAGCCCTCTCTGGGGATGAAGAACCCTCCCCAGCTGGAAGATGATGCACTTGAAGGCTC AGCAAGCAACACACAAGGGCGTCAAGTCACTGGCCGGATTCGTGCCTCCCTTGTCCTGATACTGAAGACCATCAGAAGAAGACTCCCGTT CAGCAAGTGGAGACTGGCATTCAGATTCGCTGGCCCGCATGCTGAGAGCGCAGAGATACCAAATACTGCTGGAAGGACGCAAAGGATGGC AGGATGAAAGAATGTCACAAAAAGCAGCTTTTCCACTTGATAAAAACAACTAAAACAGCAAAGCAAGTTTAAGTCCAAACACAATACTGC AGGGGTCCTTCACTGAGGATTGAATTTCAGACACAGAATACTCTTGATGACTTCAAGCCACTATGCTCCTTTGATTTGAGAAGCCACATT CCATCCCCCTCCAATTGTGATCAATACCTAGGGAGACCAATGCCCAGATGGACAAATAGCATTGACCGGCGTTAGCCCTGTTTCTCAATT CCCATCGTGTAGAGAACAGGAGTCCGCAGCTGCTGGCAGGAGACAGCATGTCAGCCGGGACTCTGCCAGGGCAGAGTATGAGCAATGCCA >In-frame_ENST00000409314_ENST00000415641_TCGA-B6-A0I9-01A_FCHSD2_chr11_72851076_-_NBPF4_chr1_108777033_length(amino acids)=335AA_start in transcript=169_stop in transcript=1176 MQPPPRKVKVTQELKNIQVEQMTKLQAKHQAECDLLEDMRLSRGPLRVDKHEIPQESLDGCCLTPSILPDLTPSYHPYWSTLYSFEDKQV SLALVDKIKKDQEEIEDQSPPCPRLSQELPEVKEQEVPEDSVNEVYLTPSVHHDVSDCHQPYSSTLSSLEDQLACSALDVASPTEAACPQ GTWSGDLSHHQSEVQVSQAQLEPSTLVPSCLRLQLDQGFHCGNGLAQRGLSSTTCSFSANADSGNQWPFQELVLEPSLGMKNPPQLEDDA -------------------------------------------------------------- >In-frame_ENST00000409418_ENST00000415641_TCGA-B6-A0I9-01A_FCHSD2_chr11_72851076_-_NBPF4_chr1_108777033_length(transcript)=1756nt_BP=503nt GGCGGCGCAGGCGGCCGACCGGGAGCGCGGACAACGCGGCTGCGGCTAACCCGCCGCCCGGCCGGCTGAGACCCTCGCGCCCCTGCTCCT GGGGCCCCCGCCCCCTCGCCGTCTCCGCCTCCTTCCTCACACACCCCCGGGCCGCCCGGGCCGCCCGGGCCCCAAGCCTTCCCGGTGCTC CTCCCTCGTCTCCTCACACTCGCTCTCTGGCTGGGGTCCGCCTGCCGCCCGCTGGCCTGCTCCCTCCGGGGCAAGTCTTGCTTCTTAAGC GCTCCTTTCACACACGCGCGCGCTCGCTGGGCCGTCCCCTCCTCTCCGGCCCTCCTCCTCCTCCTGGTCCTTGCTAACGCTGCCGTCGGG GAGGATTGATGTCCCTTCAGCATCATGCAGCCGCCGCCGAGGAAGGTGAAAGTTACACAAGAACTGAAAAACATTCAAGTTGAGCAGATG ACAAAACTTCAAGCCAAACATCAAGCAGAATGTGATTTGCTTGAAGATATGAGGCTCAGCAGGGGACCGCTGAGAGTGGACAAGCATGAA ATCCCCCAGGAGTCACTGGATGGATGTTGCTTGACTCCTTCCATCCTTCCTGACCTGACTCCCTCCTACCACCCTTATTGGAGCACTTTG TACTCTTTTGAAGACAAGCAAGTCAGCTTGGCTCTTGTAGACAAAATTAAAAAGGATCAAGAGGAGATAGAAGACCAAAGCCCACCATGC CCCAGGCTCAGCCAGGAGCTGCCAGAGGTGAAGGAGCAGGAAGTCCCAGAGGACTCTGTGAATGAAGTTTACTTGACTCCCTCAGTTCAC CATGACGTGTCTGACTGCCACCAGCCTTATAGCAGCACCTTGTCCTCATTGGAGGATCAGCTTGCCTGCTCTGCTCTGGATGTAGCCTCC CCCACCGAGGCGGCCTGTCCCCAAGGGACTTGGAGTGGAGACTTGAGCCACCACCAGTCAGAGGTGCAAGTTTCACAGGCACAGCTGGAA CCAAGCACCCTGGTGCCCAGTTGTCTGCGACTACAGCTGGATCAAGGGTTCCACTGTGGGAACGGCTTGGCCCAGCGGGGCCTTTCCTCC ACCACCTGCAGCTTCTCAGCCAATGCTGATTCTGGGAACCAATGGCCCTTCCAAGAGCTGGTTTTAGAGCCCTCTCTGGGGATGAAGAAC CCTCCCCAGCTGGAAGATGATGCACTTGAAGGCTCAGCAAGCAACACACAAGGGCGTCAAGTCACTGGCCGGATTCGTGCCTCCCTTGTC CTGATACTGAAGACCATCAGAAGAAGACTCCCGTTCAGCAAGTGGAGACTGGCATTCAGATTCGCTGGCCCGCATGCTGAGAGCGCAGAG ATACCAAATACTGCTGGAAGGACGCAAAGGATGGCAGGATGAAAGAATGTCACAAAAAGCAGCTTTTCCACTTGATAAAAACAACTAAAA CAGCAAAGCAAGTTTAAGTCCAAACACAATACTGCAGGGGTCCTTCACTGAGGATTGAATTTCAGACACAGAATACTCTTGATGACTTCA AGCCACTATGCTCCTTTGATTTGAGAAGCCACATTCCATCCCCCTCCAATTGTGATCAATACCTAGGGAGACCAATGCCCAGATGGACAA ATAGCATTGACCGGCGTTAGCCCTGTTTCTCAATTCCCATCGTGTAGAGAACAGGAGTCCGCAGCTGCTGGCAGGAGACAGCATGTCAGC >In-frame_ENST00000409418_ENST00000415641_TCGA-B6-A0I9-01A_FCHSD2_chr11_72851076_-_NBPF4_chr1_108777033_length(amino acids)=335AA_start in transcript=384_stop in transcript=1391 MQPPPRKVKVTQELKNIQVEQMTKLQAKHQAECDLLEDMRLSRGPLRVDKHEIPQESLDGCCLTPSILPDLTPSYHPYWSTLYSFEDKQV SLALVDKIKKDQEEIEDQSPPCPRLSQELPEVKEQEVPEDSVNEVYLTPSVHHDVSDCHQPYSSTLSSLEDQLACSALDVASPTEAACPQ GTWSGDLSHHQSEVQVSQAQLEPSTLVPSCLRLQLDQGFHCGNGLAQRGLSSTTCSFSANADSGNQWPFQELVLEPSLGMKNPPQLEDDA -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for FCHSD2-NBPF4 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for FCHSD2-NBPF4 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for FCHSD2-NBPF4 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | FCHSD2 | C0087031 | Juvenile-Onset Still Disease | 1 | CTD_human |
| Hgene | FCHSD2 | C3495559 | Juvenile arthritis | 1 | CTD_human |
| Hgene | FCHSD2 | C3714758 | Juvenile psoriatic arthritis | 1 | CTD_human |
| Hgene | FCHSD2 | C4552091 | Polyarthritis, Juvenile, Rheumatoid Factor Negative | 1 | CTD_human |
| Hgene | FCHSD2 | C4704862 | Polyarthritis, Juvenile, Rheumatoid Factor Positive | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies